Drugs / rhPTH(1-34)
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00532077 | Aug 2007 → Jan 2008 | osteoporosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03720886 | Oct 2018 → May 2020 | postmenopausal osteoporosis | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00741182 | Oct 2008 → Sep 2010 | — | Glostrup University Hospital, Copenhagen | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhPTH(1-34) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00532077 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human parathyroid hormone for injection ( 1-34 ) ( G56W1 )” NCT03720886 ↗ |
| Route | Subcutaneous | “Administered by subcutaneous injection” NCT03720886 ↗ |